INMB
NASDAQINmune Bio Inc.
News · 26 weeks45-25%
2025-11-022026-04-26
Mix1590d
- Other6(40%)
- SEC Filings6(40%)
- Earnings3(20%)
Latest news
25 items- PRINmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thManagement to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 7th, 2026 at 4:30pm EDT to discuss results for its quarter ended March 31, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Cal
- SECSEC Form DEF 14A filed by INmune Bio Inc.DEF 14A - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer ModelsBOCA RATON, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage biotechnology company focused on developing therapies that harness the patient's innate immune system, today announces new preclinical data for INB03 (XPro1595 for oncology). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego on April 17-22. The poster, titled, "Soluble TNF blockade overcomes tyrosine kinase inhibitors resistance in HER2-positive breast cancer," details how INB03 ("XPro™"), a first-in-class dominant-negative soluble TNF (sTNF) inhibitor, significantly enhances the anti-tumor activity of the t
- SECSEC Form 10-K filed by INmune Bio Inc.10-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Inc. Announces 2025 Results and Provides Business UpdateBOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update. Recent Corporate Highlights CORDStrom™ Platform: The CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB) is on target to file an MAA submission in the UK mid-summer, followed shortly thereafter by anticipated EMA and FDA regulatory submissions.Hosted KOL led webinar focused on the latest results from the MissionEB Phase III clinical trial highlighting the systemic disease-modifying capabili
- PRINmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: March 30th, 2026 Time: 4:30 PM Eastern Time Participa
- PRINmune Bio's MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer's DiseasePlenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer's Drug Development Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune Bio" or the "Company"), a clinical-stage inflammation and immunology company, today announced that Malú Gámez Tansey, Ph.D., Professor of Neurology at the Stark Neuroscience Research Institute at Indiana University School of Medicine, will feature the Company's Phase 2 MINDFuL trial of XPro™ (pegipanermin) as a centerpiece of her plenary presentation at AD/PD 2026 — the world's leading international conference on Alzheimer's and Parkin
- SECINmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's WebinarBoca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on the registrational pathway of XPro1595 ("XPro™") for the treatment of early Alzheimer's disease on February 27, 2026 at 9:30 a.m. ET. Post the completion of the Phase 2 MINDFuL trial, along with feedback from the FDA in a recent End-Of-Phase 2 meeting, the Company has received alignment supporting advancement to a registrational study in patients with Alzheimer's Disease with biomarkers of Inflammation. Webinar Focus: From Phase 2 Results to Phase 3 Readiness XPro™ is a next
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEBClinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET. The session will focus on the latest results from the MissionEB Phase III clinical trial, specifically highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB Webinar F
- SECINmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's DiseaseAgency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) ("INmune Bio" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it received the official minutes from its End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administration (FDA). The minutes confirm regulatory alignment on the Company's proposed integrated Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer's Disease (AD). "The outcome of the End-of-Phase 2 interaction i
- PRINmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEBPre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce time to market Boca Raton, FL, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a clinical-stage inflammation and immunology company, today announced a critical step toward the commercialization of CORDStrom™ for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The Company has formally submitted its pre-submission package for CORDStrom with the United Kingdom's Medicines and Healthcare Products Regulatory Agenc
- SECINmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic InitiativesBoca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop innovative therapies that address serious neuroinflammatory and immunologic diseases with high unmet needs. 2025 was a pivotal year for our company, highlighted by compelling clinical learnings from XPro™ in our Phase 2 Alzheimer's disease trial and significant progr
- SECINmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- SECINmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- SECSEC Form 424B5 filed by INmune Bio Inc.424B5 - Inmune Bio, Inc. (0001711754) (Filer)
- SECSEC Form 8-K filed by INmune Bio Inc.8-K - Inmune Bio, Inc. (0001711754) (Filer)
- SECAmendment: SEC Form 8-A12B/A filed by INmune Bio Inc.8-A12B/A - Inmune Bio, Inc. (0001711754) (Filer)
- SECINmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRPeer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ PlatformBoca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune's CORDStrom™ platform. The article, titled, "Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions," was published in the peer-reviewed journal Cytotherapy. One of the lead authors of the paper was INmune Bio's lead scientist for CORDStrom™ R&D, Dr Nikita M. Patel, M.Sci.,Ph.D. The article, was the result of an invitation-only working party of basic,
INMB FAQ
7 questionsWhat does INmune Bio Inc. do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in...Where does INMB stock trade?
INmune Bio Inc. (INMB) is listed on NASDAQ.What sector and industry is INMB in?
INmune Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did INmune Bio Inc. go public?
INmune Bio Inc. (INMB) completed its IPO in 2019.What are analysts saying about INMB?
INmune Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Scotiabank: Sector Underperform with a $60.00 price target on 2025-07-01.What companies are similar to INMB?
Notable peers in the same industry include IBRX (ImmunityBio Inc.), GRPH (Graphite Bio Inc.), PALI (Palisade Bio Inc.), PRVB (Provention Bio Inc.), GOSS (Gossamer Bio Inc.). Compare INMB side-by-side with any of them on Quantisnow.How can I track INMB on Quantisnow?
Quantisnow aggregates INmune Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INMB to receive live email and push alerts on every new disclosure.